The safety of treatment options for elderly people with acute myeloid leukemia

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

(2015) Alan K. Burnett et al.   BLOOD

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS

(2015) Raya Mawad et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia

(2015) Anya K Hotinski et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502

(2015) Steven M. Devine et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

(2015) Shundong Cang et al.   Journal of Hematology & Oncology

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

(2015) Farhad Ravandi et al.   LANCET ONCOLOGY

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

(2015) Jean-Pierre J Issa et al.   LANCET ONCOLOGY

Epigenetic modifiers in normal and malignant hematopoiesis

(2015) Jessica N Haladyna et al.   Epigenomics

Targeting the Microenvironment in Acute Myeloid Leukemia

(2015) Armin Rashidi et al.   Current Hematologic Malignancy Reports

Molecularly targeted therapies for acute myeloid leukemia

(2015) E. M. Stein   Hematology-American Society of Hematology Education Program

Antigen-specific immunotherapies for acute myeloid leukemia

(2015) S. A. Buckley et al.   Hematology-American Society of Hematology Education Program

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

(2014) J. E. Lancet et al.   BLOOD

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

(2014) H. Dohner et al.   BLOOD

How I treat the older patient with acute myeloid leukemia

(2014) G. Ossenkoppele et al.   BLOOD

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults

(2014) Heidi D. Klepin et al.   JOURNAL OF CLINICAL ONCOLOGY

Polypharmacy and Potentially Inappropriate Medication Use in Older Adults with Cancer Undergoing Chemotherapy: Effect on Chemotherapy-Related Toxicity and Hospitalization During Treatment

(2014) Ronald J. Maggiore et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients

(2014) G Visani et al.   LEUKEMIA

The relevance of a geriatric assessment for elderly patients with a haematological malignancy – A systematic review

(2014) M.E. Hamaker et al.   LEUKEMIA RESEARCH

Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia

(2014) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

Crenolanib is a selective type I pan-FLT3 inhibitor

(2014) C. C. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment

(2014) Alessandro Isidori et al.   Expert Review of Hematology

Understanding and targeting cancer stem cells: therapeutic implications and challenges

(2013) Ke Chen et al.   ACTA PHARMACOLOGICA SINICA

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

(2013) A. K. Burnett et al.   BLOOD

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

(2013) S. Nand et al.   BLOOD

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia

(2013) H. D. Klepin et al.   BLOOD

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

(2013) Hagop M. Kantarjian et al.   CANCER

The Hallmarks of Aging

(2013) Carlos López-Otín et al.   CELL

Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?

(2013) Ciara Freeman et al.   EXPERT OPINION ON PHARMACOTHERAPY

Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors

(2013) Theresa Hahn et al.   JOURNAL OF CLINICAL ONCOLOGY

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

(2013) Jorge Cortes et al.   LANCET ONCOLOGY

Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes

(2013) Alexander E. Sherman et al.   LEUKEMIA RESEARCH

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients

(2013) Alessandro Isidori et al.   Expert Review of Hematology

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

(2012) G. J. Ossenkoppele et al.   BLOOD

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

(2012) G. L. Uy et al.   BLOOD

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

(2012) N. Vey et al.   BLOOD

Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells

(2012) Hsing-Chen Tsai et al.   CANCER CELL

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

(2012) B. Deschler et al.   HAEMATOLOGICA

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

(2012) D. A. Pollyea et al.   HAEMATOLOGICA

Survival for older patients with acute myeloid leukemia: a population-based study

(2012) B. Oran et al.   HAEMATOLOGICA

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

(2012) G Ramsingh et al.   LEUKEMIA

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

A clinical trial of supervised exercise for adult inpatients with acute myeloid leukemia (AML) undergoing induction chemotherapy

(2012) Shabbir M.H. Alibhai et al.   LEUKEMIA RESEARCH

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

(2011) S. Kayser et al.   BLOOD

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

(2011) M. A. Sekeres et al.   BLOOD

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

(2011) Scott R. Daigle et al.   CANCER CELL

Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review

(2011) Naval Bajwa et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

(2011) R. B. Walter et al.   HAEMATOLOGICA

The Feasibility of Inpatient Geriatric Assessment for Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia

(2011) Heidi D. Klepin et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

(2011) J E Lancet et al.   LEUKEMIA

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

(2010) T. A. Fehniger et al.   BLOOD

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

(2010) Sergio Amadori et al.   BRITISH JOURNAL OF HAEMATOLOGY

Questions regarding frontline therapy of acute myeloid leukemia

(2010) Hagop Kantarjian et al.   CANCER

Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

(2010) Brian L. McClune et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia

(2010) Bob Löwenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Exercise for older adult inpatients with acute myelogenous leukemia: A pilot study

(2010) Heidi D. Klepin et al.   Journal of Geriatric Oncology

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

A phase 2 study of vorinostat in acute myeloid leukemia

(2009) E. W. Schaefer et al.   HAEMATOLOGICA

Socioeconomic Differences in Patient Survival Are Increasing for Acute Myeloid Leukemia and Multiple Myeloma in Sweden

(2009) Sigurdur Yngvi Kristinsson et al.   JOURNAL OF CLINICAL ONCOLOGY

Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid Leukemia

(2009) Arati V. Rao et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse

(2008) H. Kroeger et al.   BLOOD

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

(2008) S. Faderl et al.   BLOOD

CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells

(2008) D. Krige et al.   CANCER RESEARCH

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia

(2007) Claudiu Plesa et al.   CANCER